Please assess the completion status of the following clinical trial:

Trial Title: Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~AT ENROLLMENT:~* Subject must be 18-60 years of age.~* Subject must read and sign a copy of the approved Consent Form~* Female subjects must be using an effective birth control method.~INCLUSION CRITERIA AT DAY -28~* Subject must read and sign a copy of the approved Consent Form~AT CHALLENGE:~* Female subjects must be using an effective birth control method.~* Subject must have a serum neutralizing antibody titer of less than or equal to 1:4 to rhinovirus type 39~Exclusion Criteria:~AT ENROLLMENT:~* Current cancer diagnosis or immunosuppressive therapy in the last 6 months~* Any clinically significant abnormalities of the upper respiratory tract~* Any clinically significant acute or chronic respiratory illness~* Any clinically significant bleeding tendency by history~* Hypertension that requires treatment with antihypertensive medications~* History of angina or other clinically significant cardiac disease~* Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study~* History of regular use (more than 3 days in 7) of tobacco products within the preceding two weeks~* History of drug or alcohol abuse in the 6 months preceding the study~EXCLUSION CRITERIA AT DAY -28~* Antibiotic use within 3 months prior to study start~* Female subjects with a positive urine pregnancy screen.~* History of use of probiotics in the preceding 2 weeks.~EXCLUSION CRITERIA AT CHALLENGE:~* Any upper respiratory infection or allergic rhinitis in the two weeks prior to the start of the study~* Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study~* Use of any anti-inflammatory (steroids or NSAIDs) or cough/cold preparation in the two weeks prior to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Bifidobacterium animalis lactis Bl-04 (Type: EXPERIMENTAL): Bifidobacterium animalis subspecies lactis Bl-04 as powder mixed into drink.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.

Based on this trial design, predict the completion outcome and termination type (if applicable).